Ocular Surface Disease

Cationic emulsion drops are characterized by their ability to retain cyclosporine A on the ocular surface.

The dynamic muscle stimulation device is a noninvasive option for patients experiencing lower lid laxity and impaired blinking.

Annual reports of the occurrence of adverse effects associated with the use of cosmetics increased from 2006 to 2018, then decreased from 2018 to 2021.

Preservatives may disrupt the ocular surface, contributing to poor adherence.

This year was brimming with advancements in eye care.

According to Mile Brujic, OD, FAAO, low-level light therapy (LLLT) and intense pulsed light have demonstrated tremendous benefits for his patients.

Aurion Biotech announced that Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent efficacy, especially in the high-dose group, with favorable safety and tolerability profiles.

The University of Colorado study found that patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

Inside the role of blepharitis in ocular surface disease and effective management strategies.

All 6 biomarkers in the study demonstrated improvement with the treatment of lifitegrast, according to Thimons.

The retrospective study investigated and analyzed the severity and frequency of ocular pain and factors affecting it among DED patients living in high altitudes above 2500 meters during the COVID-19 pandemic.

Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.

Tracy Doll, OD, FAAO, details portions of the Tear Film and Ocular Surface Society Lifestyle Report, which discussed certain risk factors that we may have for development of ocular surface dryness or dry eye.

What we know and what we do not know…yet.

Lisa Hornick, OD, MBA, FAAO, outlines key findings from the report on the impacts of healthy cosmetic habits and reducing digital eye strain.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, tackled new and exciting ways to tackle meibomian gland dysfunction alongside fellow ocular surface specialist Rana Taji, OD, MSc, FAAO, at AAOpt 2024.

Dr. Justin Schweitzer's 2024 AAOpt talk will cover the latest advancements in ocular drug delivery, including topical, implant, and contact lens-based methods that can improve patient quality of life, adherence, and financial burden.

The lipid-containing lubricating drop established noninferiority in comfort when compared to non-lipid drops, and the lipid-containing group also exhibited statistically significant improvements in visual quality at both day 7 and day 30, highlighting the potential benefits of this formulation for patients.

At the Tear Film and Ocular Surface meeting in Venice, Dr. Melissa Toyos shares findings on the mechanism of action of brimonidine tartrate.

New research sheds light on how the dry eye medication lifitegrast works beyond the ocular surface, targeting the underlying immune system to provide relief for patients.

There’s more to dry eye treatment than eye drops.

Reproxalap was previously found to be statistically superior to vehicle for the primary endpoint of ocular discomfort (P=0.004) in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial.